Wilate Market Report 2026

Wilate Market Overview

• The Wilate market growth in the historic period has been driven by improved diagnosis of bleeding disorders, expansion of hemophilia treatment centers • Market expansion is supported by increasing focus on personalized bleeding disorder management, rising adoption of home infusion therapies • Growth Driver: Rising Prevalence Of Bleeding Disorders Fuels Growth In The Market • Market Trend: FDA Grants Orphan Drug Exclusivity For Treatment Of Von Willebrand Disease • North America was the largest region in 2025.

What Is Covered Under Wilate Market?

Wilate is a medication used to treat or prevent bleeding episodes in individuals with certain bleeding disorders, such as von Willebrand disease (VWD) and hemophilia A. It provides von Willebrand factor (VWF) and factor VIII, essential for blood clotting. The main types of indication for wilate are hemophilia A and von Willebrand disease (vWD). Hemophilia A is a hereditary condition caused by a lack of clotting factor VIII, resulting in impaired blood clotting and increased bleeding risk. It is distributed through various distribution channels, such as hospitals and clinics, retail pharmacies, and online pharmacies, and used by several end users, including adults and geriatrics.

What Is The Wilate Market Growth Forecast?

The growth in the forecast period can be attributed to increasing focus on personalized bleeding disorder management, rising adoption of home infusion therapies, expansion of advanced plasma-derived products, growing investments in rare hematology treatments, increasing demand for long-term disease management solutions. Major trends in the forecast period include increasing adoption of plasma-derived therapies, rising demand for prophylactic bleeding disorder treatment, growing use of combination clotting factor products, expansion of home-based infusion models, enhanced focus on treatment safety and consistency.

What Are The Drivers Of The Wilate Market?

The rising prevalence of bleeding disorders is expected to propel the growth of the wilate market going forward. Bleeding disorders are conditions where the blood fails to clot correctly, resulting in prolonged or excessive bleeding. The prevalence of bleeding disorders is due to genetic factors, liver disease, vitamin K deficiency, and immune system disorders. Wilate replaces missing clotting factors such as Factor VIII or von Willebrand factor, helping to control and prevent bleeding episodes. This treatment improves clotting ability, reduces bleeding risks, and promotes healing for those with bleeding disorders. For instance, in Mya 2025, according to Pfizer Inc a US-based biopharmaceutical corporation, in the UK, the haemophilia A and B patient population exceeded 11,800 individuals in the 2023/2024 period. Therefore, the rising prevalence of bleeding disorders is driving the growth of the wilate industry. The increasing healthcare expenditure is set to propel the growth of the Wilate market moving forward. Healthcare expenditure is the total spending on healthcare services, including costs for medical treatments, hospital care, pharmaceuticals, insurance, and public health programs. Healthcare expenditure is increasing due to an aging population, rising healthcare demands, medical advancements, chronic diseases, and expanded access to services. Rising healthcare investments improve access to advanced treatments for bleeding disorders, such as Wilate. This increased funding drives the broader adoption of innovative therapies, leading to better patient outcomes. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with growth of 0.9% in 2022. Therefore, the increasing healthcare expenditure is driving the growth of the wilate industry.

Key Players In The Global Wilate Market

Major companies operating in the wilate market are Octapharma USA Inc.

Global Wilate Market Trends and Insights

The key trend in the wilate market is obtaining drug approval by authorities to facilitate adoption and expand its presence in the treatment of bleeding disorders. Drug approval is the process by which regulatory authorities evaluate and authorize a new drug for sale and use, ensuring its safety, efficacy, and quality based on clinical trial data. For instance, in April 2024, Octapharma USA, Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted orphan drug exclusivity to Wilate, a von Willebrand factor or coagulation factor VIII complex (human) lyophilized powder for intravenous injection. This designation establishes Wilate as the first von Willebrand factor concentrate approved for routine prophylaxis in all types of von Willebrand disease (VWD), designed to reduce bleeding episodes in both adults and children aged six and older. The FDA's orphan drug status provides Wilate with up to seven years of market exclusivity, representing a major advancement in the treatment of VWD, a condition that affects up to 1% of the U.S. population.

What Defines the Wilate Market?

The wilate market consists of sales of vials, associated administration kits, infusion sets, and sterile syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Wilate Market Report 2026?

The wilate market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the wilate industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.